Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.
Last trade$295.25
Day change-$6.46 (-2.14%)
Day range$292.86 – $306.61
Volume154,867
Market cap$6.04B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$6.04B
Price / earnings
117.27×
Price / book
6.28×
Price / sales
23.78×
EV / sales
28×
EV / EBITDA
108.99×
Profitability
Earnings per share
$2.57
Return on assets
2.3%
Return on equity
5.35%
Dividend yield
0%
Liquidity and leverage
Debt / equity
1.17×
Current ratio
1.22×
Quick ratio
1.19×
Cash ratio
0.11×
Cash flow
Price / cash flow
66.3×
Price / free cash flow
66.59×
Free cash flow
$90.63M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for LGND, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$78.75M
$63.69M
$51.72M
$59.67M
$115.46M
$47.63M
$45.33M
$42.81M
Cost of revenue
$12.86M
$11.31M
$11.37M
$2.99M
$11.9M
$11.17M
$13.11M
$2.84M
Gross profit
$65.89M
$52.38M
$40.35M
$56.67M
$103.56M
$36.46M
$32.23M
$39.98M
Selling, general and administrative
$72.62M
$29.12M
$20.84M
$25.03M
$28.45M
$20.18M
$18.8M
$25.61M
Research and development
$2.77M
$14.67M
$2.15M
$3.51M
$21.02M
$6.57M
$50.09M
$4.43M
Total operating expenses
$81.65M
$43.79M
$22.98M
$42.83M
$49.01M
$26.74M
$68.89M
$68.86M
Operating income
-$15.76M
$8.59M
$17.37M
$13.84M
$54.55M
$9.72M
-$36.66M
-$28.89M
Interest expense
-$2.9M
-$1.75M
-$1.75M
-$1.79M
-$910K
-$1.15M
-$867K
-$883K
Income before taxes
-$44.09M
$64.3M
-$24.26M
$56.78M
$141.14M
$11.22M
-$50.18M
-$39.2M
Income taxes
-$15.61M
$15.8M
-$10.91M
$12M
$23.86M
$6.38M
-$7.73M
-$8.11M
Net income
-$28.49M
$48.51M
-$13.35M
$44.78M
$117.27M
$4.85M
-$42.45M
-$31.09M
Net income attributable to common shareholders
-$28.49M
$48.51M
-$13.35M
$44.78M
$117.27M
$4.85M
-$42.45M
-$31.09M
EBITDA
-$5.44M
$16.81M
$25.58M
$28.25M
$62.82M
$18.24M
-$27.89M
$10.31M
Basic earnings per share
-$1.43
$2.42
-$0.67
$2.33
$5.99
$0.25
-$2.21
-$1.64
Diluted earnings per share
-$1.43
$2.22
-$0.67
$2.09
$5.68
$0.24
-$2.21
-$1.67
Recent news
Company coverage with links to the original publishers.
Ligand Pharmaceuticals announced that its senior management team will participate in three upcoming investor conferences in September 2026: Wells Fargo Healthcare Conference (September 8), Citi 2026 Biopharma Back to School Conference (September 10), and H.C. Wainwright 28th Annual Global Investment Conference (September 14). The company will host fireside chats and one-on-one meetings with investors at these events.
As tech stocks cool and market concentration risks increase, investors should diversify into overlooked sectors. Healthcare, insurance, and regional banking are quietly building momentum. Three recommended stocks are Ligand Pharmaceuticals (royalty-based biotech model with strong growth projections), Aflac (insurance with 44-year dividend history and pet insurance growth), and Atlantic Union Bankshares (regional bank with stable fundamentals and 3.5% dividend yield).
The article compares two biotech companies: CRISPR Therapeutics, which has achieved its first gene-editing product approval for sickle cell disease but faces significant losses and customer concentration risks, versus Viking Therapeutics, a clinical-stage company targeting the obesity and metabolic disorder markets with no approved products yet. While both are highly speculative, the author favors CRISPR due to its existing revenue and approved treatment, despite Viking's potentially larger market opportunity.
XOMA Royalty Corporation announced quarterly preferred stock dividends for Series A and Series B preferred shareholders, with Series A receiving $0.53906 per share and Series B receiving $0.52344 per depositary share, payable on July 15, 2026. The company also announced the redemption of all outstanding preferred stock at $25.00 per share on July 14, 2026, in connection with its pending merger with Ligand Pharmaceuticals through Flex Merger Sub, Inc. Additionally, the record date for CVR distribution to common stockholders has been set for July 13, 2026.
Ligand Pharmaceuticals announced it will host an Investor Day in New York City on December 8, 2026, featuring presentations from senior management on the company's strategy, investment activity, royalty portfolio, and long-term financial outlook. A live webcast will be available through the company's Investor Relations website.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
Ex-dividend
Amount / share
Pay date
Type
Jul 2, 2010
$0.458
Jul 1, 2010
unknown
Apr 3, 2007
$15.00
Apr 19, 2007
special
Stock splits
Historical share-structure events and their execution dates.